Literature DB >> 7094941

Congenital microangiopathic hemolytic anemia: report of a Japanese girl.

T Shinohara, S Miyamura, E Suzuki, K Kobayashi.   

Abstract

A 4-year-old Japanese girl had hemolytic anemia, thrombocytopenia, distorted and fragmented red cells in the peripheral blood, and megakaryocytosis in the bone marrow from the newborn period. These features were temporarily relieved and prevented by the infusion of fresh frozen plasma from healthy donors. This would indicate a deficiency in the patient's plasma of factor(s) that inhibit platelet aggregation in the blood vessels. An attempt to demonstrate possible in vitro deficiency of the platelet aggregation-prohibiting factor in the patient's plasma was unsuccessful. Laboratory examinations ruled out red cell fragility, abnormalities of red cell enzymes, abnormal hemoglobins, or immune reaction as underlying mechanisms. Our patient, together with three other patients in the literature with similar clinical features, may constitute a clinical entity that could be called "congenital microangiopathic hemolytic anemia".

Entities:  

Mesh:

Year:  1982        PMID: 7094941     DOI: 10.1007/BF00441153

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  9 in total

1.  Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis.

Authors:  M C BRAIN; J V DACIE; D O HOURIHANE
Journal:  Br J Haematol       Date:  1962-10       Impact factor: 6.998

2.  Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency.

Authors:  I SCHULMAN; M PIERCE; A LUKENS; Z CURRIMBHOY
Journal:  Blood       Date:  1960-07       Impact factor: 22.113

3.  Atypical congenital haemolytic anaemia.

Authors:  J V DACIE; P L MOLLISON; N RICHARDSON; J G SELWYN; L SHAPIRO
Journal:  Q J Med       Date:  1953-01

4.  Matter M, Hartmann JR, Kautz J, DeMarsh QB, Finch CA. A study of thrombopoiesis in induced acute thrombocytopenia. Blood. 1960;15(1):174-185.

Authors: 
Journal:  Blood       Date:  2016-04-21       Impact factor: 22.113

5.  Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma.

Authors:  E C Lian; D R Harkness; J J Byrnes; H Wallach; R Nunez
Journal:  Blood       Date:  1979-02       Impact factor: 22.113

6.  Treatment of thrombotic thrombocytopenic purpura with plasma.

Authors:  J J Byrnes; M Khurana
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

7.  Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.

Authors:  R M Bukowski; J W King; J S Hewlett
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

8.  Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia.

Authors:  J D Upshaw
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

9.  Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?

Authors:  G Remuzzi; R Misiani; D Marchesi; M Livio; G Mecca; G de Gaetano; M B Donati
Journal:  Lancet       Date:  1978-10-21       Impact factor: 79.321

  9 in total
  2 in total

Review 1.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome.

Authors:  Y Sasahara; S Kumaki; Y Ohashi; M Minegishi; H Kano; F Bessho; S Tsuchiya
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.